Benelux Morning Notes

Kinepolis: June 2025 Box office revenue/ attendance in US/Canada and France down. Utilities – Offshore Wind: Big Not So Beautiful Bill

Morning Notes : AED BB, AKZA NA, MAAT FP

: AED BB, AKZA NA, MAAT FP

MaaT Pharma Partnership with Clinigen secures MaaT013's EU commerciali...

MaaT signed a licensing, distribution, and commercial supply agreement with Clinigen in Europe for Xervyteg (MaaT013, microbiome therapy, enema formulation) in aGvHD for a € 10.5m upfront, € 18m in milestones, and mid-thirties flat royalty on sales. We believe this deal serves as validation of MaaT013's potential, and see the partnership as a de-risking event for MaaT013's commercialisation in Europe, given Clinigen's experience commercialising in haemato-oncology, with 3 products currently on t...

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 07/02/2025

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 07/02/2025

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 02/07/2025

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 02/07/2025

ODDO : Raising our 2025 market forecast, rotation towards chip makers ...

ODDO : Relèvement de notre prévision de marché 2025, rotation engagée ...

Morning Notes : ARGX BB, BFIT NA, PNL NA, QFG BB, UMI BB, BTLS BB, ONW...

: ARGX BB, BFIT NA, PNL NA, QFG BB, UMI BB, BTLS BB, ONWD BB, JDEP NA

argenx FDA FAERS reporting flags Vyvgart Hytrulo in routine update

Yesterday during trading hours, the FDA flagged worsening of CIDP with Vyvgart Hytrulo as a new safety signal via a routine update to the FDA adverse event reporting system (FAERS), which sent the argenx' stock down approx. 8%. While CIDP worsening was also reported in patients switching between treatments from IVig to SCig in the PATH study, physicians navigate treatment switches carefully, and based on argenx' own post-marketing surveillance,

Arcadis/Let's see how 2H25 works out/HOLD

After contact with IR, we learned that 2Q25 has its challenges, mostly in line with 1Q. Idle time due to the ending of large contracts and ramping up of new ones was a factor and additionally, more markets encounter difficulties led by Mobility which suffers from a serious slowdown in the UK and Australia. Also, Places weakens. Resilience is doing better but not strong enough to compensate for the other GBAs. We fine-tune our estimates, expecting virtually no organic growth and no margin improve...

Benelux Morning Notes

Colruyt: 146 Okay stores to be opened on Sundays as of early 2026. Fugro: Expansion of existing contract with Petrobras

argenx FIRST LOOK: ARGX-119 Ph1b shows POC in CMS, Ph3 in preparation

argenx announced its plan to advance the clinical development of ARGX-119 (muscle-specific kinase [MuSK] agonist antibody) to a registrational study in patients with congenital myasthenic syndromes (CMS) following the analysis of topline data from the phase 1b study, which showed consistent improvements through the 12-week study across multiple efficacy scores. This marks the 3rd candidate to advance to phase 3 from argenx' internal pipeline, which in our view supports the company's future growt...

Morning Notes : AGFB BB, ARGXb BB, FUR NA, NEXTAb BB, RET BB

: AGFB BB, ARGXb BB, FUR NA, NEXTAb BB, RET BB

Fugro Securing $340m multi-year subsea inspection contracts with Petro...

Last Friday Fugro reported it has secured four Petrobras contracts for subsea inspection and monitoring in Brazil, valued at approximately $340m over four years starting in 4Q25 with optional one-year extensions. Three contracts are renewals under improved terms, while one is new and incremental. All were already included in Fugro's 12-month backlog as of March 2025. Each contract is vessel-specific, with two operated by Fugro and two by partners, all equipped with ROVs. The scope includes expan...

Colruyt/Divestment of loss-making French activity/BUY

We reiterate our BUY on Colruyt but reduce our target price from €45.5 to €44 following Colruyt's FY24/25 results. We believe that the competitive environment should improve for Colruyt in the upcoming months, noting (1) we lap tough comps on competitors opening stores on Sundays; (2) Colruyt will open its 146 OKay stores on Sunday as of early 2026, thanks to a change in Belgian regulation; and (3) reduced GDP growth forecasts in Belgium, which should benefit discounters. Valuation remains undem...

Fugro/Weak 1H25, better 2H25/BUY

Led by the disappearance of US offshore wind, Fugro continues to suffer from a downturn. We expect a weak second quarter, following the headwinds of the first quarter with lower activity levels combined with a couple of vessels not yet back into service. We foresee a YoY EBIT decline of 50% in 2Q25. However, it also looks the trough is passed with potential for a higher activity level for 2H25 and beyond. The main reason is the higher fleet presence and clients finally proceeding with long-await...

Colruyt Group N.V: 1 director

A director at Colruyt Group N.V bought 10,750 shares at 36.900EUR and the significance rating of the trade was 90/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...